[CAS NO. 691852-58-1] Nesbuvir
PRODUCTS SPECIFICATIONS [691852-58-1]
DESCRIPTION [691852-58-1]
Overview
| MDL | MFCD13152403 |
|---|---|
| Molecular Weight | 446.49 |
| Molecular Formula | C22H23FN2O5S |
| SMILES | O=C(C1=C(C2=CC=C(F)C=C2)OC3=CC(N(CCO)S(=O)(C)=O)=C(C4CC4)C=C13)NC |
6 Publications Citing Use of MCE
Summary
Nesbuvir is a nonnucleoside inhibitor of the hepatitis C virus ( HCV ) nonstructural protein 5B ( NS5B ) polymerase.
IC50 & Target
EC50: 9 nM (NS3 V170A ), 13 nM (NS3 V170A ), 15 nM (NS3 K583T ), 13 nM (NS5B I424V ) [1]
In Vitro
Replicon cells are treated with 1 mg/mL G418 and combinations of the two compounds. Nesbuvir (HCV-796) is added to 40 or 80 nM (approximately 10 and 20 times the EC 50 in a 3-day replicon inhibition assay, respectively) and Boceprevir is added to 400 or 800 nM (approximately 2 and 4 times the EC 50 , respectively). The EC 50 s for Nesbuvir and Boceprevir for the parental replicon in the transient expression assay are comparable to those obtained in the 3-day inhibition assay with the stable replicon cells; the EC 50 for Nesbuvir in the transient expression assay is 14 nM, whereas it is 5 nM for the stable replicon; and the EC 50 for Boceprevir in the transient expression assay is 608 nM, whereas it is 201 nM for the stable replicon [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Among a huge variety of yet characterized nucleoside and non-nucleoside inhibitors (NNI), the benzofurane derivative NNI Nesbuvir (HCV-796) is demonstrated to yield significant antiviral effects in mice with chimeric human livers and in patients infected with HCV. HCV-796 binds to a hydrophobic binding pocket at the “palm” domain of NS5B; however, its mode of inhibition remains to be defined [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00367887 | Wyeth is now a wholly owned subsidiary of Pfizer|ViroPharma |
Hepatitis C
|
October 2006 | Phase 2 |
| NCT00407173 | Wyeth is now a wholly owned subsidiary of Pfizer|ViroPharma |
Healthy
|
November 2006 | Phase 1 |
| NCT00385190 | Wyeth is now a wholly owned subsidiary of Pfizer |
Healthy
|
July 2006 | Phase 1 |
| NCT00314054 | Wyeth is now a wholly owned subsidiary of Pfizer|ViroPharma |
Hepatitis C|Hepatic Insufficiency
|
May 2006 | Phase 1 |
| NCT00500721 | Wyeth is now a wholly owned subsidiary of Pfizer|ViroPharma |
Healthy
|
June 2007 | Phase 1 |
| NCT00410254 | Wyeth is now a wholly owned subsidiary of Pfizer |
Healthy
|
June 2007 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 50 mg/mL ( 111.98 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.2397 mL | 11.1985 mL | 22.3969 mL |
| 5 mM | 0.4479 mL | 2.2397 mL | 4.4794 mL |
| 10 mM | 0.2240 mL | 1.1198 mL | 2.2397 mL |
References
- [1] Flint M, et al. Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034). Antimicrob Agents Chemother. 2009 Feb;53(2):401-11.
- [2] Reich S, et al. Mechanisms of activity and inhibition of the hepatitis C virus RNA-dependent RNA polymerase. J Biol Chem. 2010 Apr 30;285(18):13685-93.